Galectin Therapeutics Inc. Aktie News

Bestimmte Aktien sind derart schlechte Wetten, dass sie selbst in Bullenmärkten voraussichtlich an Boden verlieren.

NORCROSS, Ga., 14. Aug. 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), der führende Entwickler von Therapeutika, die Galectin-Proteine targeting, berichtete heute Finanzergebnisse und gab ein Geschäftsupdate für die drei Monate zum 30. Juni 2026 bekannt.

Vorsitzender Richard E. Uihlein wandelt ausstehende Schuldverschreibungen aus fünf Kreditlinien in Stammaktien um Die Transaktion beseitigt etwa 105,8 Mio. USD an Verbindlichkeiten und erhöht die Marktkapitalisierung NORCROSS, Ga.

NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabo...

NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liv...

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026.

NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension...

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.  Investors are encouraged to contact attorney Lesley F.